Novant Health
Novant Health
Charlotte, North Carolina, United States7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | Angina Pectoris, Chest Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2026-09-30 | NCT05102019 | |
| A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-09-28 | NCT03462719 | |
| A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05702034 | |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-09-25 | NCT05552222 | |
| A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 | 2026-09-25 | NCT05453903 | |
| Left vs Left Randomized Clinical Trial | Arrhythmias, Cardiac, Cardiac Conduction System Disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrioventricular block, atrioventricular dissociation, cardiovascular disorder, heart disorder, heart failure | Recruiting | Not applicable | 2025-10-02 | NCT05650658 | |
| Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 1 | 2025-04-10 | NCT04215809 |